Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population
Abstract
No abstract available
![]() |
Jacques A NUNES : Connect in order to contact the contributor
https://amu.hal.science/hal-03623103
Submitted on : Tuesday, March 29, 2022-2:39:15 PM
Last modification on : Wednesday, August 2, 2023-11:16:05 AM